Fig. 4From: Therapeutic novelties in migraine: new drugs, new hope?Overview of patients (%) achieving 2-h pain freedom in rimegepant phase III clinical trials. *Study 301; vs. placebo, p < 0.003. Study 302; vs. placebo, p < 0.001Back to article page